Retatrutide Phase 3 Results: What the TRIUMPH Program Data Shows
Evidence review of retatrutide's TRIUMPH phase 3 program. What the triple GLP-1/GIP/glucagon agonist data shows for weight loss and metabolic health, and how phase 2 results compare to the emerging phase 3 picture.
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three hormone receptors: GLP-1, GIP, and glucagon. It is in Phase 3 development under the TRIUMPH clinical trial program and is not FDA-approved or available outside clinical trials.
This article summarizes the published evidence from Phase 2 and the available Phase 3 data, clearly distinguishing what has been confirmed at each stage.
What Makes Retatrutide Different
Every approved GLP-1 medication targets one or two incretin receptors. Retatrutide adds a third.
| Medication | Mechanism | Receptors |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | GLP-1 agonist | GLP-1 |
| Tirzepatide (Mounjaro, Zepbound) | Dual incretin agonist | GLP-1 + GIP |
| Retatrutide | Triple agonist | GLP-1 + GIP + Glucagon |
The role of the glucagon receptor is what sets retatrutide apart from tirzepatide. While glucagon raises blood glucose in a fasting state, its receptor in the liver drives fat oxidation and thermogenesis in brown adipose tissue. In retatrutide, the GLP-1 and GIP components counterbalance the glucose-raising effect of glucagon activation, allowing the fat-burning and energy-expenditure benefits without worsening blood sugar [pmid-38367045].
This mechanism is described as additive: each receptor target contributes independently to weight loss and metabolic improvement, suggesting greater total efficacy than single- or dual-target approaches.
Phase 2 Results: Established Evidence
The clearest picture of retatrutide’s efficacy comes from its Phase 2 program. These are published, peer-reviewed results in leading journals.
NEJM Phase 2 Obesity Trial (Jastreboff et al., 2023)
The landmark Phase 2 trial published in the New England Journal of Medicine enrolled adults with obesity but without type 2 diabetes [pmid-37366315]. At 48 weeks:
- 24.2% mean weight loss at the 12mg highest dose
- 17.5% weight loss at the 8mg dose
- 93% of participants at the 12mg dose achieved at least 10% weight loss
- 83% achieved at least 15% weight loss
- Weight loss was still progressing at 48 weeks — no plateau observed at any dose
These results were notable for the absence of a weight loss plateau, which has historically been a limitation of GLP-1 monotherapy.
Phase 2 Type 2 Diabetes Trial (Rosenstock et al., 2023)
A separate Phase 2 trial in participants with type 2 diabetes showed [pmid-37385280]:
- HbA1c reduction of 2.02% at the 12mg dose over 36 weeks
- 82% of participants achieved HbA1c of 6.5% or below
- 16.9% body weight reduction despite the shorter 36-week duration
Phase 2 Liver Disease Trial (Sanyal et al., 2024)
A Phase 2a study in metabolic dysfunction-associated steatotic liver disease (MASLD) demonstrated [pmid-38858523]:
- 81-82% reduction in liver fat content at 48 weeks
- 89-93% of treated participants achieved normal liver fat levels (below 5%)
- 0% in the placebo group achieved liver fat normalization
The glucagon receptor component is thought to be responsible for the direct hepatic fat-reduction effect, beyond what would be expected from weight loss alone.
TRIUMPH Phase 3 Program: What We Know
Eli Lilly launched the TRIUMPH program to evaluate retatrutide across multiple populations and indications. This is where Phase 3 data is being generated.
Important caveat: Phase 3 data from the TRIUMPH program is at different stages of publication and reporting. The information below accurately reflects what has been publicly reported as of early 2026. Phase 3 data should not be extrapolated to populations or endpoints not yet studied.
TRIUMPH-4: The First Published Phase 3 Data
TRIUMPH-4 enrolled adults with obesity and moderate-to-severe knee osteoarthritis. It is currently the most mature Phase 3 dataset publicly available [pmid-41090431]:
- 28.7% mean weight loss at 68 weeks — the highest body weight reduction ever reported in a Phase 3 pharmacological trial
- 71.2 lbs average weight loss from baseline
- Significant improvements in knee pain (WOMAC pain scores) and physical function
- Consistent with and exceeding Phase 2 estimates at the same dose
What TRIUMPH-4 does not tell us: This trial enrolled a specific population (obesity + osteoarthritis) over 68 weeks. Cardiovascular outcomes, long-term durability beyond 68 weeks, and comparative data against tirzepatide or semaglutide head-to-head are not yet established.
Other Active TRIUMPH Trials
The broader TRIUMPH program includes multiple ongoing trials evaluating different populations and outcomes. Several Phase 3 readouts are expected through 2025-2026, including general obesity populations, obesity with type 2 diabetes, and a long-term cardiovascular outcomes trial (TRIUMPH-Outcomes). Full Phase 3 efficacy and safety across all populations will not be known until these trials are completed.
How It Compares: Context Table
Cross-trial comparisons require caution — different populations, protocols, and follow-up durations make direct head-to-head inferences unreliable. These figures should be understood as estimates from separate trials, not equivalents.
| Treatment | Trial Program | Weight Loss | Trial Duration | FDA Status |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | STEP-1 | ~15-17% | 68 weeks | FDA Approved (2021) |
| Tirzepatide 15mg (Zepbound) | SURMOUNT-1 | ~20-22% | 72 weeks | FDA Approved (2023) |
| Retatrutide 12mg | TRIUMPH-4 (Phase 3) | ~28.7% | 68 weeks | Investigational |
| Retatrutide 12mg | Phase 2 (NEJM) | ~24.2% | 48 weeks | Investigational |
Key caveat: The SURMOUNT-5 head-to-head trial showed tirzepatide outperforming semaglutide 2.4mg (20.2% vs 13.7% at 72 weeks). No equivalent head-to-head trial between retatrutide and tirzepatide has reported results. The TRIUMPH-5 trial is ongoing.
What Remains Unknown
Despite impressive efficacy signals, important gaps remain before retatrutide can be fully evaluated:
Long-term safety beyond 68 weeks: Cardiovascular outcomes, rare adverse events, and long-term tolerability require the ongoing TRIUMPH-Outcomes trial to mature. Glucagon receptor activation at therapeutic doses has not been assessed over multi-year periods.
Cardiovascular outcomes: Semaglutide demonstrated a 20% reduction in major adverse cardiovascular events (SELECT trial). Whether retatrutide achieves comparable cardiovascular protection is unknown — TRIUMPH-Outcomes is underway but will take years.
Head-to-head comparisons: TRIUMPH-5 is evaluating retatrutide versus tirzepatide directly. Without that data, cross-trial weight loss comparisons are inherently uncertain.
Post-discontinuation effects: What happens to body weight and metabolic parameters after stopping retatrutide is unstudied. Weight regain after GLP-1 cessation is a documented phenomenon with other agents and likely applies here.
Regulatory approval status: Retatrutide has not been submitted for FDA approval as of early 2026. No product claiming to be retatrutide available outside clinical trials is legitimate — any such product is not the investigational compound studied in these trials.
What’s Next
Eli Lilly has multiple TRIUMPH trials in progress through 2025-2026. If Phase 3 results confirm Phase 2 efficacy and the safety profile is acceptable, an NDA submission to the FDA could follow, with potential approval in the 2026-2027 timeframe — though this timeline is speculative and depends on data maturity and regulatory review.
The most clinically significant outstanding question is the cardiovascular outcome trial. For semaglutide and tirzepatide, cardiovascular outcome data dramatically expanded prescribing confidence. Similar data for retatrutide will be essential for broad adoption.
Bottom Line
Retatrutide has the most robust efficacy signal of any obesity treatment in development. Phase 2 data is published in peer-reviewed journals including the NEJM, showing 24.2% weight loss at 48 weeks. The first Phase 3 data (TRIUMPH-4) shows 28.7% weight loss at 68 weeks in a specific obesity population.
The outstanding questions — cardiovascular outcomes, head-to-head versus tirzepatide, long-term safety — are not minor caveats. They are the data that will determine whether retatrutide’s efficacy advantage over approved agents translates into clinical practice.
For now, retatrutide represents the most promising next-generation obesity compound in Phase 3 development, with substantial Phase 2 evidence and early Phase 3 confirmation. Phase 2 data is confirmed. Full Phase 3 picture: pending.
This article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug available only through clinical trials. Consult a qualified healthcare provider for medical decisions.
Sources & Citations
- 2
- 3
- 5
- 6
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.